Classic Hodgkin Lymphoma Clinical Trial
Official title:
A Phase III Randomized, Open-label, Multicenter Clinical Study of IMM01 (Timdarpacept) in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin Lymphoma
The purpose of this study is to compare efficacy of IMM01 plus Tiselizumab with physician's choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of IMM01 plus Tiselizumab. The primary study hypotheses are that IMM01 plus Tiselizuma is superior to physician's choice chemotherapy with respect to progression-free survival (PFS) and overall survival (OS).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03233347 -
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03712202 -
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT05833984 -
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02758717 -
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT01771107 -
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02166463 -
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
|
Phase 3 | |
Completed |
NCT00654732 -
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04788043 -
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT05955105 -
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT06235047 -
Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)
|
||
Recruiting |
NCT06164275 -
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT05179603 -
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
|
Phase 2 | |
Active, not recruiting |
NCT03907488 -
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
|
Phase 3 | |
Not yet recruiting |
NCT05949931 -
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06377540 -
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03057795 -
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
|
Phase 2 |